Tuesday Jan 31 | HealthCentral
Relovair: New Medicine for COPD
Developing new medications and getting them from the lab to your neighborhood pharmacy as safe and effective - is a long, complicated process, requiring a great deal of care.
Pearl Therapeutics Announces Successful Completion of Phase 2b Safety ...
Pearl Therapeutics Inc. today announced the completion of two Phase 2b clinical studies of PT003 , the Company's investigational inhaled combination bronchodilator product for the treatment of patients with moderate-to-severe COPD.
Also on Topix